Aiforia Technologies Plc – Managers' Transactions
Aiforia Technologies Plc Company release, Managers’ Transactions, September 20, 2024 03:30 p.m. EEST
Aiforia Technologies Plc – Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Musta Aukko Oy
Position: Member of the Board/Deputy member
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer
Name: Pekka Mattila
Position: Member of the Board
Issuer: Aiforia Oyj
LEI: 743700TJRVBX7420Y723
Notification type: INITIAL NOTIFICATION
Reference number: 76518/7/6
____________________________________________
Transaction date: 2024-09-19
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: DISPOSAL
(X) Executed under portfolio or asset management
Transaction details
(1): Volume: 3972 Unit price: 3.83 EUR
Aggregated transactions (1):
Volume: 3972 Volume weighted average price: 3.83 EUR
____________________________________________
Transaction date: 2024-09-20
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000507934
Nature of transaction: DISPOSAL
(X) Executed under portfolio or asset management
Transaction details
(1): Volume: 1912 Unit price: 3.83 EUR
Aggregated transactions (1):
Volume: 1912 Volume weighted average price: 3.83 EUR
Further inquiries
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc
tel. +358405009878
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com